We read with great interest and attention the paper by Buonfrate et al. that was published in the International Journal of Antimicrobial Agents [1] . It concluded that a) high-dose ivermectin was safe, b) there was no significant difference in viral load reduction between trial arms, and 3) mild/moderate side effects were more frequent with the highest dose of ivermectin.
Viral Load Reduction and High-Dose Ivermectin in Early Treatment: A Reappraisal
Simone Tedeschi;
2022-01-01
Abstract
We read with great interest and attention the paper by Buonfrate et al. that was published in the International Journal of Antimicrobial Agents [1] . It concluded that a) high-dose ivermectin was safe, b) there was no significant difference in viral load reduction between trial arms, and 3) mild/moderate side effects were more frequent with the highest dose of ivermectin.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0924857922000759-main3.pdf
solo utenti autorizzati
Descrizione: Articolo in rivista
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
192.34 kB
Formato
Adobe PDF
|
192.34 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Viral_load_reappraisal.pdf
solo utenti autorizzati
Descrizione: Articolo in rivista
Tipologia:
Documento in Pre-print
Licenza:
Copyright dell'editore
Dimensione
882.45 kB
Formato
Adobe PDF
|
882.45 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
